LYRA THERAPEUTICS INC's ticker is LYRA and the CUSIP is 55234L105. A total of 32 filers reported holding LYRA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $49,882,067 | -4.9% | 12,757,562 | 0.0% | 1.66% | +9.6% |
| Q2 2023 | $52,433,579 | +185.2% | 12,757,562 | +39.5% | 1.52% | +179.6% |
| Q1 2023 | $18,384,927 | -36.0% | 9,146,730 | 0.0% | 0.54% | -32.6% |
| Q4 2022 | $28,720,732 | -37.3% | 9,146,730 | 0.0% | 0.81% | -39.4% |
| Q3 2022 | $45,825,000 | -11.3% | 9,146,730 | 0.0% | 1.33% | -17.9% |
| Q2 2022 | $51,679,000 | +298.9% | 9,146,730 | +183.8% | 1.62% | +522.7% |
| Q1 2022 | $12,955,000 | -53.9% | 3,222,560 | -50.0% | 0.26% | +19.8% |
| Q4 2021 | $28,100,000 | -4.4% | 6,445,120 | +100.0% | 0.22% | -49.2% |
| Q3 2021 | $29,403,000 | -43.2% | 3,222,560 | -50.0% | 0.43% | +27.1% |
| Q2 2021 | $51,754,000 | +38.6% | 6,445,120 | +100.0% | 0.34% | -28.8% |
| Q1 2021 | $37,349,000 | +1.7% | 3,222,560 | -0.0% | 0.47% | +19.8% |
| Q4 2020 | $36,737,000 | +2.0% | 3,222,561 | 0.0% | 0.39% | -25.1% |
| Q3 2020 | $36,028,000 | -1.4% | 3,222,561 | 0.0% | 0.53% | -11.1% |
| Q2 2020 | $36,543,000 | – | 3,222,561 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,777,251 | $3,572,275 | 0.74% |
| Perceptive Advisors | 9,146,730 | $18,384,927 | 0.54% |
| PURA VIDA INVESTMENTS, LLC | 1,996,972 | $4,013,914 | 0.41% |
| VR Adviser, LLC | 924,170 | $1,857,582 | 0.36% |
| Nantahala Capital Management | 2,220,830 | $4,463,868 | 0.34% |
| Ikarian Capital, LLC | 343,685 | $711,427 | 0.16% |
| Soleus Capital Management, L.P. | 592,417 | $1,190,758 | 0.12% |
| Clearline Capital LP | 119,128 | $239,448 | 0.04% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 146,800 | $303,876 | 0.01% |
| Tower Research Capital LLC (TRC) | 9,972 | $20 | 0.00% |